MX2022001266A - Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. - Google Patents
Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.Info
- Publication number
- MX2022001266A MX2022001266A MX2022001266A MX2022001266A MX2022001266A MX 2022001266 A MX2022001266 A MX 2022001266A MX 2022001266 A MX2022001266 A MX 2022001266A MX 2022001266 A MX2022001266 A MX 2022001266A MX 2022001266 A MX2022001266 A MX 2022001266A
- Authority
- MX
- Mexico
- Prior art keywords
- hbv
- treatment
- induced diseases
- infection
- dihydropyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente se proporcionan derivados de dihidropirimidina que son útiles en el tratamiento o la prevención de la infección por VHB o de enfermedades inducidas por VHB, más particularmente de la infección crónica por VHB o de enfermedades inducidas por la infección crónica por VHB, así como también aplicaciones farmacéuticas o médicas de estos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019098571 | 2019-07-31 | ||
PCT/CN2020/105765 WO2021018238A1 (en) | 2019-07-31 | 2020-07-30 | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001266A true MX2022001266A (es) | 2022-05-03 |
Family
ID=74228605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001266A MX2022001266A (es) | 2019-07-31 | 2020-07-30 | Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220281865A1 (es) |
EP (1) | EP4003997A4 (es) |
JP (1) | JP2022543010A (es) |
KR (1) | KR20220041853A (es) |
CN (1) | CN114174300A (es) |
AU (1) | AU2020322598A1 (es) |
BR (1) | BR112022001564A2 (es) |
CA (1) | CA3146997A1 (es) |
MX (1) | MX2022001266A (es) |
WO (1) | WO2021018238A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022257942A1 (en) * | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10013126A1 (de) * | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
BR112015004113A2 (pt) * | 2012-09-10 | 2017-07-04 | Hoffmann La Roche | 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
BR112015028873A2 (pt) * | 2013-05-17 | 2017-07-25 | Hoffmann La Roche | heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b |
PL3114128T3 (pl) * | 2014-03-07 | 2019-06-28 | F. Hoffmann-La Roche Ag | Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B |
WO2017011552A1 (en) * | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2017064156A1 (en) * | 2015-10-16 | 2017-04-20 | F. Hoffmann-La Roche Ag | Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
-
2020
- 2020-07-30 KR KR1020227005441A patent/KR20220041853A/ko unknown
- 2020-07-30 CN CN202080053674.1A patent/CN114174300A/zh active Pending
- 2020-07-30 MX MX2022001266A patent/MX2022001266A/es unknown
- 2020-07-30 AU AU2020322598A patent/AU2020322598A1/en active Pending
- 2020-07-30 BR BR112022001564A patent/BR112022001564A2/pt not_active Application Discontinuation
- 2020-07-30 EP EP20847775.2A patent/EP4003997A4/en not_active Withdrawn
- 2020-07-30 WO PCT/CN2020/105765 patent/WO2021018238A1/en unknown
- 2020-07-30 CA CA3146997A patent/CA3146997A1/en active Pending
- 2020-07-30 US US17/597,894 patent/US20220281865A1/en active Pending
- 2020-07-30 JP JP2022506303A patent/JP2022543010A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020322598A1 (en) | 2022-03-24 |
JP2022543010A (ja) | 2022-10-07 |
EP4003997A1 (en) | 2022-06-01 |
CA3146997A1 (en) | 2021-02-04 |
EP4003997A4 (en) | 2023-08-02 |
KR20220041853A (ko) | 2022-04-01 |
CN114174300A (zh) | 2022-03-11 |
BR112022001564A2 (pt) | 2022-07-12 |
WO2021018238A1 (en) | 2021-02-04 |
US20220281865A1 (en) | 2022-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2021000147A (es) | Combinacion terapeutica que comprende lamivudina | |
NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
NZ735575A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
NZ741957A (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MD3359146T2 (ro) | Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală | |
WO2016086153A3 (en) | Use of hsp90 inhibitors for the treatment of hiv infections and aids | |
MX2022001261A (es) | Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb. | |
EP3814326A4 (en) | DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE | |
EP3790866A4 (en) | DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2020001256A (es) | Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos. | |
PH12018500450A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2022001266A (es) | Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. | |
MX2018011095A (es) | Compuestos de carbapenem. | |
MA40805A (fr) | Compositions pharmaceutiques à action prolongée contre l'hépatite c | |
MX2022001271A (es) | Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |